JP7252908B2 - Ｓ１ｐ１活性を調節するための化合物およびその使用法 - Google Patents

Ｓ１ｐ１活性を調節するための化合物およびその使用法 Download PDF

Info

Publication number
JP7252908B2
JP7252908B2 JP2019569457A JP2019569457A JP7252908B2 JP 7252908 B2 JP7252908 B2 JP 7252908B2 JP 2019569457 A JP2019569457 A JP 2019569457A JP 2019569457 A JP2019569457 A JP 2019569457A JP 7252908 B2 JP7252908 B2 JP 7252908B2
Authority
JP
Japan
Prior art keywords
pain
cancer
optionally substituted
neuropathy
optionally
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019569457A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020523390A5 (enExample
JP2020523390A (ja
Inventor
フィリップ・マイケル・ピティス
ロバート・ユージーン・ボイド
タマーラ・アン・ミスコウスキー・ダウバート
マイケル・ジョン・ホーキンス
グオドン・リウ
エイミー・クロンビー・スピアシュナイダー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Trevena Inc
Original Assignee
Trevena Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trevena Inc filed Critical Trevena Inc
Publication of JP2020523390A publication Critical patent/JP2020523390A/ja
Publication of JP2020523390A5 publication Critical patent/JP2020523390A5/ja
Priority to JP2023046107A priority Critical patent/JP2023078375A/ja
Application granted granted Critical
Publication of JP7252908B2 publication Critical patent/JP7252908B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D249/18—Benzotriazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2019569457A 2017-06-14 2018-06-12 Ｓ１ｐ１活性を調節するための化合物およびその使用法 Active JP7252908B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023046107A JP2023078375A (ja) 2017-06-14 2023-03-23 Ｓ１ｐ１活性を調節するための化合物およびその使用法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762519575P 2017-06-14 2017-06-14
US62/519,575 2017-06-14
PCT/US2018/036989 WO2018231745A1 (en) 2017-06-14 2018-06-12 Compounds for modulating s1p1 activity and methods of using the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023046107A Division JP2023078375A (ja) 2017-06-14 2023-03-23 Ｓ１ｐ１活性を調節するための化合物およびその使用法

Publications (3)

Publication Number Publication Date
JP2020523390A JP2020523390A (ja) 2020-08-06
JP2020523390A5 JP2020523390A5 (enExample) 2021-07-26
JP7252908B2 true JP7252908B2 (ja) 2023-04-05

Family

ID=64660688

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019569457A Active JP7252908B2 (ja) 2017-06-14 2018-06-12 Ｓ１ｐ１活性を調節するための化合物およびその使用法
JP2023046107A Pending JP2023078375A (ja) 2017-06-14 2023-03-23 Ｓ１ｐ１活性を調節するための化合物およびその使用法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023046107A Pending JP2023078375A (ja) 2017-06-14 2023-03-23 Ｓ１ｐ１活性を調節するための化合物およびその使用法

Country Status (9)

Country Link
US (2) US11912693B2 (enExample)
EP (1) EP3638235A4 (enExample)
JP (2) JP7252908B2 (enExample)
KR (1) KR102892521B1 (enExample)
CN (1) CN110831593A (enExample)
AU (2) AU2018282747B2 (enExample)
CA (1) CA3066423A1 (enExample)
IL (1) IL271149B2 (enExample)
WO (1) WO2018231745A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201819376A (zh) 2016-10-06 2018-06-01 比利時商健生藥品公司 經取代之１Ｈ－咪唑並［４，５－ｂ］吡啶－２（３Ｈ）－酮及其作為ＧＬＵＮ２Ｂ受體調節劑之用途
EP3582783B1 (en) * 2017-02-17 2023-06-07 Trevena, Inc. 7-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same
US20180282282A1 (en) 2017-03-30 2018-10-04 Genentech, Inc. Isoquinolines as inhibitors of hpk1
IL271149B2 (en) 2017-06-14 2024-05-01 Trevena Inc Compounds for modulating s1p1 activity and methods of using the same
TW202019905A (zh) 2018-07-24 2020-06-01 瑞士商赫孚孟拉羅股份公司 異喹啉化合物及其用途
TW202024053A (zh) 2018-10-02 2020-07-01 美商建南德克公司 異喹啉化合物及其用途
US11612606B2 (en) 2018-10-03 2023-03-28 Genentech, Inc. 8-aminoisoquinoline compounds and uses thereof
WO2020132493A1 (en) * 2018-12-21 2020-06-25 Indiana University Research And Technology Corporation Compositions and methods for suppressing and/or treating hiv-infection and/or a related clinical condition thereof
EA202191890A1 (ru) 2019-01-18 2022-02-03 Астразенека Аб Ингибиторы pcsk9 и способы их применения
US11459336B2 (en) 2019-06-14 2022-10-04 Janssen Pharmaceutica Nv Pyrazine carbamates and their use as GluN2B receptor modulators
WO2020249785A1 (en) 2019-06-14 2020-12-17 Janssen Pharmaceutica Nv Substituted heteroaromatic pyrazolo-pyridines and their use as glun2b receptor modulators
MX2021015508A (es) 2019-06-14 2022-01-31 Janssen Pharmaceutica Nv Carbamatos de piridina y su uso como moduladores del receptor glun2b.
WO2020249802A1 (en) 2019-06-14 2020-12-17 Janssen Pharmaceutica Nv Substituted pyrazolo-pyrazines and their use as glun2b receptor modulators
CR20210580A (es) 2019-06-14 2022-01-31 Janssen Pharmaceutica Nv Amidas depirazol-piridina sustituidos y su uso como moduladores del receptor glun2b
BR112021025136A2 (pt) 2019-06-14 2022-01-25 Janssen Pharmaceutica Nv Pirazolo[4,3-b]piridinas substituídas e seu uso como moduladoras do receptor de glun2b
JP7667097B2 (ja) 2019-06-14 2025-04-22 ヤンセン ファーマシューティカ エヌ．ベー． 置換ピラゾロ－ピリジンアミド及びｇｌｕｎ２ｂ受容体調節因子としてのその使用
US20220315574A1 (en) * 2019-08-01 2022-10-06 Duke University Beta-Arrestin-Modulating Compounds and Methods of Using Same
BR112022003959A2 (pt) * 2019-09-05 2022-05-24 Trevena Inc Métodos para tratamento de epilepsia
CN114727977A (zh) * 2019-11-19 2022-07-08 特维娜有限公司 化合物和化合物s1p1调节剂的制备方法
US12364686B2 (en) 2020-03-27 2025-07-22 Receptos Llc Sphingosine 1 phosphate receptor modulators
WO2021257857A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Naphthyridinone compounds as jak2 v617f inhibitors
WO2021257863A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Pyrrolotriazine compounds as jak2 v617f inhibitors
US11767323B2 (en) 2020-07-02 2023-09-26 Incyte Corporation Tricyclic pyridone compounds as JAK2 V617F inhibitors
WO2022006457A1 (en) 2020-07-02 2022-01-06 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
WO2022046989A1 (en) 2020-08-27 2022-03-03 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
US11919908B2 (en) 2020-12-21 2024-03-05 Incyte Corporation Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors
KR20230154194A (ko) * 2021-02-10 2023-11-07 이칸 스쿨 오브 메디슨 엣 마운트 시나이 신장 섬유증의 치료를 위한 HIPK2의 옥사디아졸릴 디하이드로피라노[2,3-b]피리딘 억제제
WO2022182839A1 (en) 2021-02-25 2022-09-01 Incyte Corporation Spirocyclic lactams as jak2 v617f inhibitors
JP2025509672A (ja) 2022-03-17 2025-04-11 インサイト・コーポレイション Ｊａｋ２ ｖ６１７ｆ阻害剤としての三環式尿素化合物

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007116866A1 (ja) 2006-04-03 2007-10-18 Astellas Pharma Inc. ヘテロ化合物
JP2008515985A (ja) 2004-10-13 2008-05-15 ピーティーシー セラピューティクス，インコーポレーテッド ナンセンス抑制の化合物とその使用方法
JP2009520751A (ja) 2005-12-23 2009-05-28 エフ．ホフマン−ラ ロシュ アーゲー アリール−イソオキサゾロ−４−イル−オキサジアゾール誘導体
JP2011522818A (ja) 2008-06-06 2011-08-04 アボット・ラボラトリーズ 新規１，２，４オキサジアゾール化合物およびこれらの使用方法
JP2011530485A (ja) 2008-05-30 2011-12-22 メルク・シャープ・エンド・ドーム・コーポレイション 新規な置換されたピラゾール、１，２，４−オキサジアゾールおよび１，３，４−オキサジアゾール
WO2013181931A1 (en) 2012-06-07 2013-12-12 Syngenta Participations Ag Pesticidally active pyridyl- and pyrimidyl- substituted thiazole derivatives
WO2016028959A1 (en) 2014-08-20 2016-02-25 Bristol-Myers Squibb Company Substituted bicyclic compounds
WO2016209809A1 (en) 2015-06-22 2016-12-29 Arena Pharmaceuticals, Inc. Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid(compound1) for use in sipi receptor-associated disorders
WO2017136309A1 (en) 2016-02-01 2017-08-10 Ironwood Pharmaceuticals, Inc. USE OF sGC STIMULATORS FOR THE TREATMENT OF NONALCOHOLIC STEATOHEPATITIS (NASH)

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4997199A (en) 1998-07-16 2000-02-07 Axys Pharmaceuticals, Inc. Process for the synthesis of benzopyran derivatives
EP1247810B1 (en) * 2001-04-04 2005-09-07 Pfizer Products Inc. Novel benzotriazoles anti-inflammatory compounds
AU2003255803A1 (en) 2002-08-23 2004-03-11 Celltech R And D Limited Quinazolinone derivatives
AU2003263323A1 (en) * 2002-09-07 2004-03-29 Celltech R And D Limited Quinazolinone derivatives
AU2003256003A1 (en) * 2002-09-18 2004-04-08 Pfizer Products Inc. Novel oxazole and thiazole compounds as transforming growth factor (TGF) inhibitors
US7919519B2 (en) 2005-11-23 2011-04-05 Epix Pharmaceuticals Inc. S1P receptor modulating compounds and use thereof
US7803940B2 (en) 2006-11-24 2010-09-28 Takeda Pharmaceutical Company Limited Heteromonocyclic compound or a salt thereof having strong antihypertensive action, insulin sensitizing activity and the like production thereof and use thereof for prophylaxis or treatment of cardiovascular diseases, metabolic diseases and/or central nervous system diseases
TW201000099A (en) 2008-06-20 2010-01-01 Amgen Inc S1P1 receptor agonists and use thereof
WO2010043000A1 (en) 2008-10-17 2010-04-22 Akaal Pharma Pty Ltd S1p receptors modulators and their use thereof
TW201116212A (en) 2009-10-29 2011-05-16 Du Pont Heterobicycle-substituted azolyl benzene fungicides
EP2555772B1 (en) 2010-04-08 2017-01-11 Merck Sharp & Dohme Corp. Oxazole derivatives useful as modulators of faah
WO2011146089A1 (en) * 2010-05-21 2011-11-24 Abbott Laboratories Modulators of 5-ht receptors and methods of use thereof
EP2635573B1 (en) 2010-11-03 2014-10-01 Bristol-Myers Squibb Company Heterocyclic compounds as s1p1 agonists for the treatment of autoimmune and vascular diseases
CA2817071C (en) 2010-11-08 2018-04-24 Omeros Corporation Treatment of addiction and impulse-control disorders using pde7 inhibitors
BR112013028886A2 (pt) * 2011-05-10 2016-08-09 Gilead Sciences Inc compostos heterocíclicos fundidos como moduladores dde canal de sódio
CA2850394C (en) 2011-10-12 2019-05-21 University Health Network Indazole compounds as kinase inhibitors and method of treating cancer with same
EP2885287B1 (en) 2012-08-20 2017-09-20 Syngenta Participations AG Pesticidally active pyridyl- and pyrimidyl- substituted pyrazole derivatives
ES2813450T3 (es) 2013-08-19 2021-03-23 Univ California Compuestos y métodos para tratar un trastorno epiléptico
EP2853532B1 (en) 2013-09-28 2020-12-09 Instytut Farmakologii Polskiej Akademii Nauk 1,2,4-oxadiazole derivatives as allosteric modulators of metabotropic glutamate receptors belonging to group III
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
IL271149B2 (en) 2017-06-14 2024-05-01 Trevena Inc Compounds for modulating s1p1 activity and methods of using the same
BR112022003959A2 (pt) 2019-09-05 2022-05-24 Trevena Inc Métodos para tratamento de epilepsia
CN114727977A (zh) 2019-11-19 2022-07-08 特维娜有限公司 化合物和化合物s1p1调节剂的制备方法

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008515985A (ja) 2004-10-13 2008-05-15 ピーティーシー セラピューティクス，インコーポレーテッド ナンセンス抑制の化合物とその使用方法
JP2009520751A (ja) 2005-12-23 2009-05-28 エフ．ホフマン−ラ ロシュ アーゲー アリール−イソオキサゾロ−４−イル−オキサジアゾール誘導体
WO2007116866A1 (ja) 2006-04-03 2007-10-18 Astellas Pharma Inc. ヘテロ化合物
JP2011530485A (ja) 2008-05-30 2011-12-22 メルク・シャープ・エンド・ドーム・コーポレイション 新規な置換されたピラゾール、１，２，４−オキサジアゾールおよび１，３，４−オキサジアゾール
JP2011522818A (ja) 2008-06-06 2011-08-04 アボット・ラボラトリーズ 新規１，２，４オキサジアゾール化合物およびこれらの使用方法
WO2013181931A1 (en) 2012-06-07 2013-12-12 Syngenta Participations Ag Pesticidally active pyridyl- and pyrimidyl- substituted thiazole derivatives
WO2016028959A1 (en) 2014-08-20 2016-02-25 Bristol-Myers Squibb Company Substituted bicyclic compounds
WO2016209809A1 (en) 2015-06-22 2016-12-29 Arena Pharmaceuticals, Inc. Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid(compound1) for use in sipi receptor-associated disorders
WO2017136309A1 (en) 2016-02-01 2017-08-10 Ironwood Pharmaceuticals, Inc. USE OF sGC STIMULATORS FOR THE TREATMENT OF NONALCOHOLIC STEATOHEPATITIS (NASH)
JP2019507185A (ja) 2016-02-01 2019-03-14 アイアンウッド ファーマシューティカルズ インコーポレイテッド 非アルコール性脂肪性肝炎（ＮＡＳＨ）の処置のためのｓＧＣ刺激物質の使用

Also Published As

Publication number Publication date
AU2018282747B2 (en) 2024-01-18
IL271149B1 (en) 2024-01-01
US20230234946A1 (en) 2023-07-27
JP2023078375A (ja) 2023-06-06
AU2018282747A1 (en) 2020-01-30
US11912693B2 (en) 2024-02-27
US20210188826A1 (en) 2021-06-24
KR20200020781A (ko) 2020-02-26
IL271149B2 (en) 2024-05-01
EP3638235A1 (en) 2020-04-22
CN110831593A (zh) 2020-02-21
WO2018231745A1 (en) 2018-12-20
AU2024202449A1 (en) 2024-05-02
BR112019026478A2 (pt) 2020-07-14
IL271149A (en) 2020-01-30
EP3638235A4 (en) 2021-06-09
CA3066423A1 (en) 2018-12-20
KR102892521B1 (ko) 2025-11-27
JP2020523390A (ja) 2020-08-06

Similar Documents

Publication Publication Date Title
JP7252908B2 (ja) Ｓ１ｐ１活性を調節するための化合物およびその使用法
US10968235B2 (en) N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2
EP3094627B1 (en) 1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and and compositions thereof for inhibiting the activity of shp2
TW201912639A (zh) Ｓｈｐ２之八氫環戊烷并[c]吡咯別構抑制劑
CN114585360B (zh) 使用其治疗癫痫的方法
KR20140105445A (ko) 비아릴 에테르 술폰아미드 및 치료제로서의 그의 용도
JP2012521428A (ja) 疼痛治療用のｐ２ｘ３受容体アンタゴニスト
TW200908983A (en) Heterocyclic compounds and uses thereof
CN103717593B (zh) 调节激酶的组合物和方法
KR20170082494A (ko) 결정 형태의 글루타미나아제 억제제
TW201022247A (en) 1-(arylsulfonyl)-4-(piperazin-1-yl)-1H-benzimidazoles as 5-hydroxytryptamine-6 ligands
JP7316216B2 (ja) ５員アザ複素環を含有するデルタ－オピオイド受容体調節化合物、その使用方法及び製造方法
KR101589837B1 (ko) 디히드록시 치환기를 포함하는 trpv1 길항제 및 그의 용도
US20210246120A1 (en) Method of preparation and use of phosphoinositide 3-kinase inhibitors in treating cancer
JP2009537626A (ja) ９−ヒドロキシエリプチシン誘導体による悪性表現型の復帰変異
BR112019026478B1 (pt) Compostos, ou sais farmaceuticamente aceitáveis dos mesmos, para modulação da atividade de s1p1; composições farmacêuticas compreendendo os mesmos e seus usos
HK40019187A (en) Compounds for modulating s1p1 activity and methods of using the same
HK40076272A (en) Methods of treating epilepsy using the same
HK40016700A (en) 5-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same
HK40016699B (zh) 含有7元氮杂杂环的δ阿片受体调节化合物及其使用和制备方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210607

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210607

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220526

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220628

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220927

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230124

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230222

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230324

R150 Certificate of patent or registration of utility model

Ref document number: 7252908

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150